Oculis Holding AG
NASDAQ:OCSBiotechnology
-$0.28 today
- Market cap
- $456.20M
- Beta
- 0.13
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$1.61
Volume 0.31M
Average 0.65M
OCS Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Oculis Holding AGNASDAQ: OCS
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of CHF 157.43K rose 28.0% year over year, ahead of the -7.4% change in trailing-twelve-month depreciation & amortization. Over 3 fiscal years it compounded at +20.4% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +28.0% holds above the trailing-twelve-month pace of -7.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
CHF · from the income statement
- Latest · FY2025
- 521.45K CHF
- Year-over-year change
- +28.4%
- 4-year CAGR
- +22.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 521.45K | +28.4% |
| FY2024 | 2024-12-31 | 406K | +41.5% |
| FY2023 | 2023-12-31 | 287K | -4.0% |
| FY2022 | 2022-12-31 | 299K | +27.2% |
| FY2021 | 2021-12-31 | 235K | — |
Depreciation & Amortization vs competitors
How OCS compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -7.4% is the 5th highest of 6, against a peer median of +20.3%.
- Depreciation & amortization amounts to 83.8% of revenue for OCS, versus a peer median of 20.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $19.5M USD | +32.3% | +88.3% | 7.3% | |
| LTM Mar 2026 | $4.63M USD | +20.3% | +27.0% | 8.9% | |
| LTM Mar 2026 | $2.45M USD | +41.2% | -1.9% | 32.1% | |
| LTM Mar 2026 | CHF 422.43K CHF | -7.4% | +20.4% | 83.8% | |
| LTM Mar 2026 | $119.64K USD | +3.7% | -17.0% | 35.9% | |
| FY2025 | $2.56K USD | -33.7% | +3.2% | — | |
| Peer median (excluding OCS) | — | +20.3% | +3.2% | 20.5% | |
Competitors are the stored peer set for OCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 686K | 0 |
| Cost of Revenue | 0 | 0 | 0 | 52.08M | 0 |
| Gross Profit | 0 | 0 | 0 | (51.4M) | 0 |
| Gross Margin | — | — | — | -7492.3% | — |
| Research & Development | 9.57M | 22.22M | 29.25M | 52.08M | 54.52M |
| Selling, General & Admin | 4.1M | 6.74M | 14.72M | 21.81M | 24.63M |
| Operating Expenses | 13.23M | 32.38M | 80.71M | 21.81M | 79.15M |
| Depreciation & Amortization | 235K | 299K | 287K | 406K | 521.45K |
| EBITDA | (13.17M) | (31.9M) | (87.09M) | (85.53M) | (93.37M) |
| EBITDA Margin | — | — | — | -12468.1% | — |
| Operating Income | (13.23M) | (32.38M) | (80.71M) | (73.2M) | (79.15M) |
| Operating Margin | — | — | — | -10671.1% | — |
| Interest Income | 21K | 126K | 1.59M | 2.17M | 1.69M |
| Interest Expense | 5.12M | 6.44M | 1.46M | 639K | 795.55K |
| Other Income / Expenses | (5.29M) | (6.27M) | (7.98M) | (12.73M) | (15.54M) |
| Income Before Tax | (18.52M) | (38.64M) | (88.7M) | (85.94M) | (94.69M) |
| Pre-Tax Margin | — | — | — | -12527.3% | — |
| Income Tax Expense | 27K | 55K | 107K | (160K) | 177.64K |
| Net Income | (18.55M) | (38.7M) | (88.8M) | (85.78M) | (94.51M) |
| Net Margin | — | — | — | -12503.9% | — |
| EPS (Basic) | (0.57) | (1.18) | (2.97) | (2.12) | (1.81) |
| EPS (Diluted) | (0.57) | (1.18) | (2.97) | (2.12) | (1.81) |
| Weighted Avg Shares | 32.73M | 32.73M | 29.9M | 40.41M | 52.36M |
| Weighted Avg Shares (Diluted) | 32.73M | 32.73M | 29.9M | 40.41M | 52.36M |
Oculis Holding AG
NASDAQ:OCS
Intrinsic Alpha fair value
Locked
Current Price
$7.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.